Literature DB >> 29777446

The degree of HIV-1 amino acid variability is strictly related to different disease progression rates.

Rossana Scutari1, Monica Faieta2, Roberta D'Arrigo3, Lavinia Fabeni1, Cristina Mussini4, Andrea Cossarizza5, Claudio Casoli6, Carlo Federico Perno7, Valentina Svicher1, Claudia Alteri1, Stefano Aquaro8.   

Abstract

The aim of this study is to evaluate the amino acid variability of HIV-1 Gp41, C2-V3, and Nef in a group of patients characterized by different disease progression rates. HIV-1 sequences were collected from 19 Long term non progressor patients (LTNPs), 9 slow progressors (SPs), and 11 rapid progressors (RPs). Phylogenetic trees were estimated by MEGA 6. Differences in amino acid variability among sequences belonging to the 3 groups have been evaluated by amino acid divergence, Shannon entropy analysis, and the number of amino acid mutations (defined as amino acid variations compared with HxB2). The involvement of amino acid mutations on epitope rich regions was also investigated. The population was mainly composed of males (74.3%) and HIV-1 subtype B strains (B: 92.32%, CRF_12BF, A1, C: 2.56% each). Viral load (log10 copies/mL) and CD4+T cell count (cells/mm3) were 3.9 (3.5-4.2) and 618 (504-857) in LTNPs, 3.3 (2.8-4.7) and 463 (333-627) in SPs, and 4.6 (4.3-5.3) and 201 (110-254) in RPs. Gp41 and C2-V3 amino acid divergence was lower in LTNP and SP strains compared to RPs (median value: 0.085 and 0.091 vs. 0.114, p = 0.005 and 0.042) and a trend of lower variability was observed for Nef (p = 0.198). A lower entropy value was observed at 10, 3, and 7 positions of Gp41, C2-V3, and Nef belonging to LTNPs and at 7, 3, and 1 positions of Gp41, C2-V3, and Nef belonging to SPs compared with RPs (p < 0.05). Focusing on epitope rich regions, again a higher degree of conservation was observed in Gp41 and C2-V3 sequences belonging to LTNPs and SPs compared to those belonging to RPs. This study shows that the extent of amino acid variability correlates with a different HIV-1 progression rate. This variability also involves CTL epitope rich regions, thus suggesting its involvement in the immune escape process modulation.

Entities:  

Keywords:  CTL epitopes; Disease progression; HIV-1; HIV-1 amino acid Shannon entropy; HIV-1 mutation rate; HIV-1 variability

Mesh:

Substances:

Year:  2018        PMID: 29777446     DOI: 10.1007/s11262-018-1571-2

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  36 in total

1.  First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection.

Authors:  Bin Wang; Meriet Mikhail; Wayne B Dyer; John J Zaunders; Anthony D Kelleher; Nitin K Saksena
Journal:  Virology       Date:  2003-07-20       Impact factor: 3.616

2.  Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.

Authors:  Stefano Aquaro; Roberta D'Arrigo; Valentina Svicher; Giovanni Di Perri; Sergio Lo Caputo; Ubaldo Visco-Comandini; Mario Santoro; Ada Bertoli; Francesco Mazzotta; Stefano Bonora; Valerio Tozzi; Rita Bellagamba; Mauro Zaccarelli; Pasquale Narciso; Andrea Antinori; Carlo Federico Perno
Journal:  J Antimicrob Chemother       Date:  2006-08-05       Impact factor: 5.790

3.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

4.  Polymorphism of gp41 glycoprotein might influence the progression to disease in HIV-1 infection.

Authors:  Valérie Potard; Zaïna Ait-Arkoub; Henri Agut
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

Review 5.  HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Authors:  Haynes W Sheppard; Connie Celum; Nelson L Michael; Stephen O'Brien; Michael Dean; Mary Carrington; Dale Dondero; Susan P Buchbinder
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

6.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

8.  Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients.

Authors:  Daniela Mologni; Paola Citterio; Barbara Menzaghi; Barbara Zanone Poma; Chiara Riva; Valentina Broggini; Alessandro Sinicco; Laura Milazzo; Fulvio Adorni; Stefano Rusconi; Massimo Galli; Agostino Riva
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

9.  A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs.

Authors:  Virginia Sandonís; Concepción Casado; Tamara Alvaro; Maria Pernas; Isabel Olivares; Soledad García; Carmen Rodríguez; Jorge del Romero; Cecilio López-Galíndez
Journal:  Virology       Date:  2009-06-25       Impact factor: 3.616

10.  Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection.

Authors:  Berta Rodés; Carlos Toro; Ellen Paxinos; Eva Poveda; Manuel Martinez-Padial; José Miguel Benito; Victoria Jimenez; Terri Wrin; Sylvina Bassani; Vincent Soriano
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

View more
  1 in total

1.  Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies.

Authors:  Jennie M Hutchinson; Kathryn A Mesa; David L Alexander; Bin Yu; Sara M O'Rourke; Kay L Limoli; Terri Wrin; Steven G Deeks; Phillip W Berman
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.